Biofrontera AG Logo

Biofrontera AG

Biopharmaceutical firm specializing in photodynamic therapy for skin conditions.

B8F | F

Overview

Corporate Details

ISIN(s):
DE000A409625 (+2 more)
LEI:
391200D6GFSVFGFQTL13
Country:
Germany
Address:
Hemmelrather Weg 201, 51377 Leverkusen

Description

Biofrontera AG is a biopharmaceutical company that specializes in dermatology. The company develops and markets innovative products for the treatment, care, and protection of the skin. Its core expertise is in photodynamic therapy (PDT), a non-invasive treatment for various skin conditions. Biofrontera's products are primarily focused on treating forms of non-melanoma skin cancer, such as actinic keratosis, field cancerization, and basal cell carcinoma. The portfolio includes both dermatological drugs and medical cosmetics.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 00:00
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2025 bis zum 30.06…
German 262.4 KB
2025-06-10 00:00
Hinweis auf Halbjahresfinanzbericht vom 01.01.2025 bis zum 30.06.2025
German 6.3 KB
2025-05-13 00:00
Konzernabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 205.3 KB
2025-05-09 00:00
Jahresabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 138.8 KB
2025-04-17 15:05
Biofrontera AG: Bekanntmachung der Einberufung zur Hauptversammlung am 28.05.20…
German 44.5 KB
2025-04-17 00:00
Hinweis auf Jahresfinanzbericht vom 14.04.2025 bis zum 13.04.2029
German 6.5 KB
2024-09-30 00:00
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2024 bis zum 30.06…
German 264.3 KB
2024-09-26 00:00
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
German 6.4 KB
2024-07-21 00:00
Ad-hoc-Meldung gemäß Art. 17 MAR in Verbindung mit § 4 Abs. 1 S. 1 Nr. 1a WpAV
German 11.8 KB
2024-05-02 00:00
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 132.6 KB
2024-05-02 00:00
Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 185.6 KB
2024-04-29 00:00 English 4.0 MB
2024-04-24 00:00
Hinweis auf Konzernabschluss vom 01.01.2023 bis zum 31.12.2023
German 6.3 KB
2023-08-31 00:00
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2023 bis zum 30.06…
German 236.4 KB
2023-08-18 00:00
Hinweis auf Halbjahresfinanzbericht vom 01.01.2023 bis zum 30.06.2023
German 6.4 KB

Automate Your Workflow. Get a real-time feed of all Biofrontera AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Biofrontera AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Biofrontera AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-03-24 Deutsche Balaton Aktiengesellschaft Close relation Buy None 7,366.00 EUR
2023-03-24 Deutsche Balaton Aktiengesellschaft Close relation Buy None 381.00 EUR
2023-03-20 Deutsche Balaton Aktiengesellschaft Close relation Buy None 7,503.16 EUR
2023-03-13 NEON Equity AG Close relation Buy None 30,627.00 EUR
2023-03-13 Deutsche Balaton Aktiengesellschaft Close relation Buy None 6,290.31 EUR
2023-03-13 Deutsche Balaton Aktiengesellschaft Close relation Buy None 635.00 EUR
2023-03-13 TO Holding 1 GmbH Close relation Buy None 575.00 EUR
2023-03-10 Deutsche Balaton Aktiengesellschaft Close relation Buy None 6,718.30 EUR
2023-03-08 Adenauer, Dr. Sven-Georg Other Buy None 140,000.00 EUR
2023-03-06 Deutsche Balaton Aktiengesellschaft Close relation Buy None 152.40 EUR

Peer Companies

An R&D-focused company developing drugs for CNS disorders and oncology.
South Korea
003000
C4 Therapeutics, Inc. Logo
Clinical-stage biopharma developing targeted protein degradation therapeutics.
United States of America
CCCC
Cadrenal Therapeutics, Inc. Logo
A late-stage biopharmaceutical company developing novel anticoagulation therapeutics.
United States of America
CVKD
CalciMedica, Inc. Logo
Develops CRAC channel inhibitors for acute inflammatory and immunologic diseases.
United States of America
CALC
Calidi Biotherapeutics, Inc. Logo
Develops stem cell platforms to deliver oncolytic viruses for cancer therapy.
United States of America
CLDI
Calliditas Therapeutics Logo
Biopharma company developing and commercializing treatments for rare diseases.
Sweden
CALTX
CALTH. Inc Logo
Develops in vitro diagnostic tools for point-of-care and self-testing.
South Korea
402420
Cambrex Logo
A CDMO providing drug substance, drug product, and analytical services.
United States of America
CBM
CAMBRIDGE NUTRITIONAL SCIENCES PLC Logo
Develops and manufactures diagnostic tests for food sensitivity and gut health.
United Kingdom
CNSL
Camp4 Therapeutics Corp Logo
Develops RNA-based therapeutics to amplify protein expression for genetic diseases.
United States of America
CAMP

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.